Amgen's New Data Signals a Turning Point for Rare Autoimmune Diseases

LONDON, UK – June 03, 2026 – In the world of rare autoimmune diseases, patients and clinicians often navigate a landscape of uncertainty, battling chronic conditions with treatments that can be as taxing as the diseases themselves. This week, at the prestigious European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, new data presented by biotechnology giant Amgen offered a significant beacon of hope, suggesting a potential shift from mere management to sustained, long-term control for two debilitating conditions.

The presentations focused on UPLIZNA® for Immunoglobulin G4-related disease (IgG4-RD) and TAVNEOS® for ANCA-associated vasculitis (AAV). The findings, drawn from both late-stage clinical trials and real-world patient cohorts, point toward a future where disease flares are preventable and the heavy reliance on long-term steroids—with their host of debilitating side effects—could become a relic of the past. For those living in the shadow of these unpredictable illnesses, this represents more than just a scientific advancement; it's a tangible difference in the pursuit of a normal life.

A New Paradigm for IgG4-Related Disease

IgG4-related disease is a condition as enigmatic as it is aggressive. It's a chronic, fibroinflammatory disorder where the body's immune system mistakenly attacks its own tissues, leading to tumor-like masses and potential organ damage. Affecting everything from the pancreas to the salivary glands, its hallmark is a pattern of unpredictable flares that can cause progressive harm. For years, the primary weapon against these flares has been high-dose glucocorticoids, a blunt instrument that, while effective at quelling inflammation, comes at a high cost of bone loss, diabetes, infections, and other serious long-term effects.

New data from the open-label extension of Amgen's Phase 3 MITIGATE trial for UPLIZNA® (inebilizumab) challenges this paradigm. The results, presented here in London, are striking. Among patients who had received UPLIZNA in the initial controlled period and continued the treatment, a remarkable 0% experienced a disease flare over the following year. Furthermore, 71.4% of these patients achieved a state of complete remission, free from both flares and the glucocorticoids they once depended on. Even for patients who initially received a placebo and then switched to UPLIZNA, the results were promising, with over 41% achieving steroid-free remission.

"For clinicians, a sustained reduction in flares and timely intervention are central to improving long-term outcomes," said Dr. John Stone, the trial's principal investigator and a professor at Harvard Medical School. "The new MITIGATE data reinforce the long-term safety and efficacy profile of UPLIZNA."

Perhaps just as importantly, the research is providing a roadmap for how to get ahead of the disease. A separate analysis from the trial identified a crucial biological signal—a rise in CD19+ B cells—that precedes a flare. These cells are part of the immune system and are targeted by UPLIZNA. This discovery is a first-of-its-kind insight into the natural history of IgG4-RD, transforming the clinical approach from reactive to potentially proactive. The ability to monitor for these biomarkers could allow doctors to intervene before a patient even feels symptoms, preventing organ damage before it occurs.

Reducing the Steroid Burden in Vasculitis

A similar story of hope and reduced treatment burden is unfolding for patients with ANCA-associated vasculitis (AAV), a group of severe diseases where inflammation of small blood vessels can lead to catastrophic damage in vital organs like the kidneys and lungs. Like IgG4-RD, the standard of care has long relied on high-dose steroids to control the life-threatening inflammation, locking patients into a difficult trade-off between managing their disease and enduring the toxic effects of treatment.

Real-world data presented for TAVNEOS® (avacopan) from two large U.S. healthcare systems offers a compelling alternative. The AQUARIUS analyses, evaluating 159 patients, demonstrated that the drug was effective in helping many achieve disease control while rapidly tapering off steroids.

"Real-world experience with TAVNEOS...demonstrates that many patients can achieve meaningful disease control with reduced reliance on glucocorticoids," noted Dr. Naomi Patel, a rheumatologist at Massachusetts General Hospital and a study investigator. She highlighted that because "prolonged steroid use carries significant risks for patients, these findings are encouraging." The data suggests that shorter steroid tapers are feasible without compromising effectiveness, a significant step toward minimizing overall steroid exposure.

This real-world validation is crucial, as it confirms that the benefits seen in controlled clinical trials translate to the complexities of everyday patient care. TAVNEOS works by targeting a specific part of the immune system's inflammatory cascade, the complement C5a receptor, thereby calming the neutrophil-driven inflammation that characterizes AAV without broadly suppressing the entire immune system.

The impact of this cannot be overstated, a sentiment echoed by patient advocates. "People living with ANCA-associated vasculitis often have limited treatment options and may rely heavily on steroids for disease control," said Joyce Kullman, executive director of the Vasculitis Foundation. "Given the challenges associated with long-term steroid use, these new data reinforce that TAVNEOS can help patients achieve disease control with reduced steroid use. For the vasculitis community, this may represent a step toward reducing treatment burden over time."

Beyond the Data: The Human and Market Impact

The data presented at EULAR 2026 underscores a broader commitment from Amgen to tackle some of the most challenging rare diseases. "Patients living with rare autoimmune diseases still face significant unmet medical needs," said Dr. Paul Burton, Amgen's chief medical officer. "The data we're presenting...reflecting our commitment to advancing the science and delivering meaningful progress for patients."

This progress has clear human and strategic implications. For patients, the prospect of flare-free, steroid-free remission means reclaiming their lives from the constant threat of relapse and the chronic toll of treatment. It means fewer hospital visits, less organ damage, and a better quality of life. The biomarker discovery in IgG4-RD, in particular, represents a fundamental shift in disease management, moving toward a personalized, predictive model of care.

From a strategic perspective, these findings solidify the company's growing leadership in the high-value rare disease market. While effective off-label treatments like rituximab have been used for these conditions, UPLIZNA and TAVNEOS offer targeted mechanisms of action backed by robust, indication-specific data. By demonstrating not just efficacy but also a superior safety profile and a reduction in the need for toxic steroids, these therapies are positioned to become the new standard of care.

The journey for patients with rare diseases is often long and arduous, marked by misdiagnosis and a frustrating trial-and-error approach to treatment. The advancements showcased this week provide more than just new therapeutic options; they offer a clearer understanding of the diseases themselves. By deconstructing the biological drivers of these illnesses, the science is paving the way for more effective, targeted strategies that prioritize not only survival but the long-term well-being and quality of life for every patient.